国产日韩午夜视频在线观看,狼友在线视频,色妞www精品视频,a天堂视频在线观看,熟女精品激情免费视频,午夜福利二区无码在线,午夜夜伦鲁鲁片免费无码,99成人福利免费视频
      歡迎來(lái)到范德生物BIOFOUNT
      范德生物中國(guó)
      范德生物產(chǎn)品購(gòu)買購(gòu)物車
      0
      搜索
      126721-07-1
      • Efegatran sulfate

      • names:

        (S)-1-(N-((S)-5-guanidino-1-oxopentan-2-yl)-N-methyl-D-phenylalanyl)pyrrolidine-2-carboxamide sulfate

      • CAS號(hào):

        126721-07-1

        MDL Number:
      • MF(分子式): C21H34N6O7S MW(分子量): 514.59
      • EINECS: Reaxys Number:
      • Pubchem ID: Brand:BIOFOUNT
      Efegatran sulfate
      貨品編碼 規(guī)格 純度 價(jià)格 (¥) 現(xiàn)價(jià)(¥) 特價(jià)(¥) 庫(kù)存描述 數(shù)量 總計(jì) (¥)
      快速詢價(jià)
      收起
      你想詢價(jià)的產(chǎn)品
      請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式,以便為您提供最好的服務(wù)。
      中文別名 Efegatran sulfate
      英文別名 Efegatran sulfate; LY294468 sulfate; LY 294468 sulfate; LY-294468 sulfate;
      CAS號(hào) 126721-07-1
      Inchi InChI=1S/C21H32N6O3.H2O4S/c1-26(16(14-28)9-5-11-25-21(23)24)18(13-15-7-3-2-4-8-15)20(30)27-12-6-10-17(27)19(22)29;1-5(2,3)4/h2-4,7-8,14,16-18H,5-6,9-13H2,1H3,(H2,22,29)(H4,23,24,25);(H2,1,2,3,4)/t16-,17-,18+;/m0./s1
      InchiKey VQRNSOAWJKHUJL-WSLRHHBVSA-N
      分子式 Formula C21H34N6O7S
      分子量 Molecular Weight 514.59
      溶解度Solubility
      性狀 Solid powder
      儲(chǔ)藏條件 Storage conditions Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).
      產(chǎn)品說(shuō)明 Efegatran sulfate(CAS:126721-07-1):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的,不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過(guò)程療,該產(chǎn)品非藥用,非食用。
      IntroductionEfegatran sulfate is an antithrombotic.
      Application1
      Application2
      Application3
      警示圖
      危險(xiǎn)性 Warning
      危險(xiǎn)性警示
      安全聲明
      安全防護(hù)
      備注
      [1]Fung AY, Lorch G, Cambier PA, Hansen D, Titus BG, Martin JS, Lee JJ, Every NR, Hallstrom AP, Stock-Novack D, Scherer J, Weaver WD. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. Am Heart J. 1999 Oct;138(4 Pt 1):696-704. PubMed PMID: 10502216.
      [2]PRIME Investigators. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. Am Heart J. 2002 Jan;143(1):95-105. PubMed PMID: 11773918.
      [3] Lijnen HR. Efegatran. Institute for drug research/IVAX. IDrugs. 2001 Jun;4(6):691-4. PubMed PMID: 16001314.
      [4] Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, Stibbe J, Müller EJ, Poortermans KJ, Deckers JW, Simoons ML. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J. 1999 Aug;20(15):1101-11. PubMed PMID: 10413640.
      [5] Smith GF, Shuman RT, Craft TJ, Gifford DS, Kurz KD, Jones ND, Chirgadze N, Hermann RB, Coffman WJ, Sandusky GE, Roberts E, Jackson CV. A family of arginal thrombin inhibitors related to efegatran. Semin Thromb Hemost. 1996;22(2):173-83. PubMed PMID: 8807715.
      6: Shetler TJ, Crowe VG, Bailey BD, Jackson CV. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Circulation. 1996 Oct 1;94(7):1719-25. PubMed PMID: 8840866.7: Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Semin Thromb Hemost. 1995;21(2):177-83. PubMed PMID: 7660140.8: Sanderson PE, Naylor-Olsen AM. Thrombin inhibitor design. Curr Med Chem. 1998 Aug;5(4):289-304. Review. PubMed PMID: 9668196.9: Tarzami ST, Wang G, Li W, Green L, Singh JP. Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost. 2006 Mar;4(3):656-63. PubMed PMID: 16460448.10: Kaiser B, Koza M, Walenga JM, Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res. 1996 May 1;82(3):257-63. PubMed PMID: 8732629.1
        對(duì)不起,暫無(wú)產(chǎn)品評(píng)價(jià)!
      MSDS
      SDS 1.0 中文
      展開
      SDS 1.0 英文
      展開
            新聞

            怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)

            細(xì)胞爬片免疫組化染色,是通過(guò)細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長(zhǎng),主要用于組織學(xué),免疫組織化學(xué)...

            2020/7/20 22:04:33

            提取病毒RNA的實(shí)驗(yàn)方法

            提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...

            2020/7/22 20:29:26

            chelex 100樹脂國(guó)產(chǎn)替代之路-BIOFOUNT范德生物

            Chelex 100螯合離子交換樹脂對(duì)銅、鐵和其他重金屬?的偏好顯著高于對(duì)鈉、鉀等一價(jià)陽(yáng)離子的偏好。它對(duì)二價(jià)...

            2025/11/4 14:22:46

            9月開學(xué)季——助研新學(xué)期 范德送好禮

            2025/8/28 15:30:55

            Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國(guó)際市場(chǎng)的雙重突破

            在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái),Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...

            2025/5/13 13:03:40

            Waxfilm實(shí)驗(yàn)室封口膜的5大突破

            Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。

            2025/5/6 17:02:07

            各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)

            微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...

            2023/7/28 10:43:09

            新一代微流控鍵合解決方案

            微流控鍵合解決方案:微流控芯片制造的一個(gè)重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是:微流控...

            2023/7/27 12:44:28

            熒光素鉀鹽使用說(shuō)明

            D-熒光素鉀鹽(K+)設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...

            2023/7/20 11:05:11

            如何選BSA(牛血清白蛋白)

            如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...

            2023/2/14 13:09:18

            My title page contents